Welcome to our dedicated page for ICU MEDICAL INC/DE SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ICU MEDICAL INC/DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ICU MEDICAL INC/DE's regulatory disclosures and financial reporting.
ICU Medical (ICUI) VP and General Counsel Virginia Ruth Sanzone reported equity award activity involving restricted and performance-based stock units. On March 7 and 8, 2026, she acquired multiple blocks of Common Stock through exercises or conversions of derivative awards, including 23,917 Performance Shares and several smaller tranches.
The filing also shows dispositions of Common Stock coded as tax-withholding events, with 13,221 shares and 1,762 shares delivered at a price of $132.00 per share to satisfy exercise price or tax liabilities. A performance stock unit grant dated March 8, 2024 was certified at 250% of target on February 11, 2026, resulting in the shares acquired. Footnotes explain that these awards are restricted stock units and performance-based restricted stock units with no purchase or exercise price and time-based vesting over three years.
ICU Medical (ICUI) executive Daniel Woolson reported multiple equity award settlements and related tax-withholding transactions. On March 7–8, 2026, he acquired ICU Medical common stock through the exercise or conversion of performance-based and other restricted stock units at an exercise price of $0.00 per share.
The filing shows Performance-based Restricted Stock Units (PRSUs) granted on March 8, 2024 were earned at 250% of target after the Compensation Committee certified performance results on February 11, 2026, resulting in common shares being issued. Code F entries reflect tax-withholding dispositions of common shares at $132.00 per share, leaving Woolson with directly owned common stock as reported after each transaction.
ICU Medical Chief Operating Officer Christian B. Voigtlander reported equity award activity involving performance-based and time-based stock units. On 3/8/2026, he exercised 71,757 performance shares at $0 per share, converting them into 71,757 shares of common stock, and his direct common stock holdings increased to 79,421 shares.
As part of this activity, 39,667 shares of common stock were disposed of at $132 per share to satisfy tax withholding obligations, leaving 39,754 shares directly owned afterward. On 3/7/2026, he also exercised 3,522 performance-based restricted stock units for 3,522 common shares, with 1,946 shares withheld at $132 per share for taxes. Footnotes explain that these awards are restricted and performance-based units with no purchase or exercise price, and recent performance certification caused the PRSUs granted on 3/8/2024 to be earned at 250% of target.
ICU Medical, Inc. reported that its Board’s Compensation Committee approved an amendment to the company’s Executive Severance Plan. The amendment, effective as of December 31, 2025, extends the plan’s expiration date by three years, from December 31, 2025 to December 31, 2028.
The Executive Severance Plan governs severance benefits for certain senior executives, so extending its term maintains the existing framework for executive departure protections. The full text of the Third Amendment to the Executive Severance Plan is provided as an exhibit and is incorporated by reference.
ICU Medical describes its 2025 business, strategy and risks as a global provider of infusion therapy, vascular access and vital care products. The company now operates through Consumables, Infusion Systems and Vital Care, selling to hospitals, distributors and alternate‑site providers in more than 100 countries.
ICU highlights the 2022 acquisition of Smiths Medical and the 2019 Pursuit Vascular deal, as well as a 2025 transaction forming a joint venture with Otsuka, under which it sold 60% of its IV Solutions business while retaining 40% and commercial responsibilities. Management emphasizes ongoing R&D investment, strong regulatory oversight in the U.S. and EU, and risks from inflation, foreign exchange, trade policy, FDA compliance, cybersecurity, supplier concentration and high leverage from the Smiths Medical acquisition.
ICU Medical reported fourth quarter 2025 revenue of $540.7 million, down from $629.8 million a year earlier, mainly reflecting the prior divestiture of its IV Solutions business within the Vital Care line. Despite lower revenue, GAAP gross margin improved to 38% from 36%.
The company posted a GAAP net loss of $15.7 million, or $(0.64) per diluted share, narrowing from a $23.8 million loss in 2024. On a non-GAAP basis, adjusted EBITDA was $98.2 million and adjusted diluted EPS was $1.91, both below the prior year.
For full-year 2025, ICU Medical generated $2.23 billion in revenue and modest GAAP net income of $0.7 million, supported by a gain on a business sale and strong operating cash flow of $179.8 million. The company reduced long-term debt and ended the year with $308.0 million in cash.
Looking to fiscal 2026, management guides GAAP net income between $26 million and $44 million and GAAP EPS between $1.03 and $1.74. ICU Medical expects adjusted EBITDA of $400–$430 million and adjusted EPS of $7.75–$8.45, assuming continued non-GAAP adjustments for items like stock compensation, amortization, restructuring, and quality-related remediation.
ICU Medical, Inc. (ICUI) insider transaction: company officer Daniel Woolson, listed as VP, GM-Infusion Capital, reported selling 2,897 shares of ICUI common stock in an open market transaction on 11/25/2025, at a price of $152.3522 per share. After this sale, he beneficially owns 11,297 shares of ICU Medical common stock.
ICU Medical (ICUI) Form 4: Director Elisha W. Finney exercised 1,285 non-qualified stock options at $103.76 and, on the same day (11/11/2025), sold 1,285 shares at $140.42. Following these transactions, she directly owns 3,995 shares.
The option carried a $103.76 exercise price, became exercisable on 06/15/2016, and expires on 01/08/2026; derivative securities beneficially owned after the transactions were 0.
ICU Medical (ICUI) disclosed a Form 4 reporting an insider sale by officer Virginia Sanzone, VP and General Counsel. She sold 930 shares of common stock on 11/11/2025 at $142.345 per share, coded “S” for sale. Following the transaction, she beneficially owns 5,456 shares, held directly. The filing notes all shares were sold at the exact price disclosed.
ICU Medical (ICUI) reported Q3 2025 results. Revenue was $536.99 million versus $589.13 million last year, with gross profit of $200.88 million. Operating income reached $13.72 million, but the company posted a net loss of $3.40 million (basic and diluted EPS -$0.14) as interest expense offset operating gains.
Year-to-date, revenue was $1.69 billion and net income $16.47 million, aided by a $44.79 million gain on sale of business tied to divesting a 60% stake in the IV Solutions business to OPF for $211.19 million cash and retaining a 40% equity-method interest. The retained interest was recorded at fair value and equity income was $1.30 million for the nine months (Q3 equity loss $1.54 million).
Cash and equivalents were $299.73 million, and long‑term debt declined to $1.31 billion from $1.53 billion at year‑end. Segment revenue mix in Q3: Consumables $285.09 million, Infusion Systems $173.91 million, and Vital Care $77.99 million. U.S. revenue was $307.13 million. Shares outstanding were 24,686,660 as of October 31, 2025.